
Historically, unfractionated heparin (UFH) with a vitamin K antagonist has been the standard treatment for deep venous thrombosis (DVT) or pulmonary embolism. More recently, low-molecular-weight heparin (LMWH) combined with vitamin K antagonists has become the most common choice, but newer target-specific oral anticoagulants have widened the range of treatment options.



